Enavogliflozin

SKU: orb1303610

Description

Enavogliflozin (DWP-16001) is a small molecule, orally administered inhibitor of the sodium-glucose cotransporter 2 (SGLT2). It is utilized in research to investigate SGLT2 function in metabolic diseases, with applications in both in vitro binding assays and in vivo models of diabetes.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1415472-28-4
• MW: 446.92
• Purity: 97.81% (May vary between batches)
• Formula: C₂₄H₂₇ClO₆
• SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1cc(Cc2ccc(cc2)C2CC2)c(Cl)c2OCCc12
• Target: SGLT
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (8.95 mM);DMSO:100 mg/mL (223.75 mM)

Bioactivity

• Target IC50:
  SGLT2:0.8 ± 0.3 nM|ERG (human):44.9 µM|SGLT2 (human):0.43 nM
• In Vitro:
  Enavogliflozin (DWP-16001), a best-in-class antidiabetic agent, functions as a selective and orally active sodium-glucose cotransporter-2 (SGLT-2) inhibitor, as supported by references .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

antidiabetic, agent, cotransporter, DWP 16001, DWP16001, DWP-16001, inhibit, orally, Enavogliflozin, Inhibitor, SGLT2, SGLT, selective, Sodium-dependent glucose cotransporters, sodium-glucose

Compound Identifiers

PubChem CID

71076840